At the time of writing, Allogene Therapeutics Inc [ALLO] stock is trading at $2.04, up 44.68%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALLO shares have gain 35.10% over the last week, with a monthly amount glided 9.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $11. On January 05, 2024, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citigroup initiated its recommendation with a Buy and recommended $7 as its price target on December 08, 2023.
For the past year, the stock price of Allogene Therapeutics Inc fluctuated between $1.32 and $5.78. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $2.04 at the most recent close of the market. An investor can expect a potential return of 1321.57% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
According to Allogene Therapeutics Inc [NASDAQ:ALLO], the company’s sales were 0.04M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at -1437.6% with Operating Profit Margin at -6501.95%, Pretax Profit Margin comes in at -6591.37%, and Net Profit Margin reading is -6591.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.58 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.68 points at the first support level, and at 1.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.25, and for the 2nd resistance point, it is at 2.46.
Ratios To Look Out For
It is important to note that Allogene Therapeutics Inc [NASDAQ:ALLO] has a current ratio of 9.35. As well, the Quick Ratio is 9.35, while the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 10693.17, the price to book ratio is 0.92.
Transactions by insiders
Recent insider trading involved Douglas Earl Martin, SVP, General Counsel, that happened on Feb 03 ’25 when 6404.0 shares were sold. CHIEF FINANCIAL OFFICER, Parker Geoffrey M. completed a deal on Feb 03 ’25 to sell 4361.0 shares. Meanwhile, Chief Technical Officer MOORE TIMOTHY L. sold 14746.0 shares on Feb 03 ’25.
